SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BNB (BNB) is a cryptocurrency . BNB has a current supply of 131,511,348.93. The last known price of BNB is 702.2705794 USD and is down -0.19 over the last 24 hours. It is currently trading on 3523 active market(s) with $1,103,086,320.06 traded over the last 24 hours. More information can be found at https://bnbchain.org/en.

Binance

Discussion centers on a reported major Binance security breach and withdrawal disruptions, raising concerns about customer fund safety and the exchanges solvency. Traders debate the reported North Korea-linked attribution against speculation about an inside job, while some cite Binances assurances that losses will be covered.

ZIM Integrated Shipping Services Ltd. engages in the provision of shipping and logistics services. It offers shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. The company was founded on June 7, 1945 and is headquartered in Haifa, Israel.

Zim Integrated Shipping Services Ltd

ZIMs raised full-year outlook, supported by strong freight rates and demand, is fueling discussion about earnings and potential dividends. Traders are also debating the uncertain Hapag-Lloyd takeover and whether a standalone company could return more value to shareholders, with some caution over insider selling and deal risk.

Hedera (HBAR) is a cryptocurrency launched in 2017. Hedera has a current supply of 50,000,000,000 with 44,327,154,878.82761615 in circulation. The last known price of Hedera is 0.07180731 USD and is down -0.57 over the last 24 hours. It is currently trading on 465 active market(s) with $36,939,739.82 traded over the last 24 hours. More information can be found at https://www.hedera.com/.

Hedera Hashgraph

HBAR is drawing attention amid a prolonged pullback toward the seven-cent area, with traders debating whether continued weakness reflects broader crypto-market pressure and persistent sell supply or presents a buying opportunity. Some holders are accumulating and citing Hederas enterprise and AI use cases, while skeptics point to weak price performance and rallies that have reversed; no single confirmed new catalyst dominates the discussion.

Occidental Petroleum Corp. engages in the exploration and production of oil and natural gas. It operates through the following segments: Oil and Gas, Chemical, and Midstream and Marketing. The Oil and Gas segment explores for, develops and produces oil and condensate, natural gas liquids, and natural gas. The Chemical segment manufactures and markets basic chemicals and vinyls. The Midstream and Marketing segment purchases, markets, gathers, processes, transports and stores oil, condensate, natural gas liquids, natural gas, carbon dioxide, and power. The company was founded in 1920 and is headquartered in Houston, TX.

Occidental Petroleum Corp.

OXY is drawing attention around oil-supply headlines, including OPEC+ keeping production targets steady and ongoing concern about Iran-related disruptions to shipping and exports. Traders are watching a potential breakout and call-heavy options activity, while others question how reliably the shares track crude prices.

Tidal Trust II - YieldMax MSTR Option Income Strategy ETF

YieldMax MSTR Option Income Strategy ETF

MSTYs sharp decline is drawing attention to its exposure to MSTR and Bitcoin, alongside concerns about NAV erosion and shrinking weekly distributions from its option-income strategy. Holders are split between buying the dip for income and betting on a crypto recovery, while critics warn the price and payouts may keep deteriorating and raise the prospect of another reverse split.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiservs earnings miss and reduced 2026 outlook are driving debate, with traders focused on weaker business performance and doubts about managements execution. Some see the sharp selloff as a value opportunity and point to turnaround potential, while speculation about asset sales and a recovery remains unconfirmed.

Twilio, Inc. engages in the development of communications software, cloud-based platforms, and services. It operates through Twilio Communications and Twilio Segments. The Twilio Communications segment includes the platforms Messaging and Voice. The Twilio Segment involves Segment, Engage, Flex, Email, and others. The company was founded by John Wolthuis, Jeffery G. Lawson, and Evan Cooke in March 2008 and is headquartered in San Francisco, CA.

Twilio Inc - Ordinary Shares Class A

Twilio Inc

Twilios quarterly beat and raised full-year outlook were overshadowed by softer Q4 organic-growth guidance, which signaled a slowdown and fueled a sharp post-earnings selloff. Traders debate whether the drop reflects justified concern about decelerating growth or an overreaction to otherwise strong results, with some watching for support and a bounce.

Stellar (XLM) is a cryptocurrency launched in 2014. Stellar has a current supply of 50,001,786,837.39707 with 35,251,444,473.510925 in circulation. The last known price of Stellar is 0.16965209 USD and is down -0.50 over the last 24 hours. It is currently trading on 848 active market(s) with $69,462,156.70 traded over the last 24 hours. More information can be found at https://www.stellar.org.

Stellar Lumens

XLMs persistent selloff and failure to hold recent levels dominate the discussion, with many traders blaming heavy token supply or broader crypto weakness; claims of ongoing Stellar Foundation selling are speculation. Bulls are buying dips and pointing to DTCC and other tokenization developments, while skeptics argue those adoption stories have not translated into price strength.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

A sharp selloff in ARM and other semiconductor stocks has traders debating whether the decline is an oversold pullback or a deeper repricing, with some blaming weakness across chipmakers and others pointing to ARMs rich valuation and negative momentum. Dip buyers cite the long-term AI and CPU-demand story, while bears expect more downside.

Magnite, Inc. provides a technology solution to automate the purchase and sale of digital advertising inventory for buyers and sellers. It features applications and services for digital advertising sellers including websites, mobile applications, and other digital media properties. The company was founded by Frank Addante, Duc Chau, Craig Roah, Julie Mattern and Brian D. Baumgart on April 20, 2007 and is headquartered in New York, NY.

Magnite Inc

Attention centers on anticipation for Magnites next earnings report, with traders looking for confirmation that connected-TV advertising can sustain growth. Views are split between dip-buyers expecting strong results and concern over recent weakness, broader ad-tech pressure, and uncertainty around digital advertisings outlook.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Healthcares strong relative performance and breakout to new highs are drawing attention as traders describe capital rotating from technology into defensive sectors. Sentiment is broadly bullish, though some caution that the rally may be extended or volatile.

SLS, IOVA, IBRX Slump In October As Biotech Stocks Hold Steady: Virginia Pension Fund Raised Stakes In All 3

Equity

Virginia Retirement Systems raised its stakes in all three stocks, with combined holdings worth nearly $3 million at September-end.

Interesting XLV Put And Call Options For December 11th

Investors in Select Sector SPDR Trust - State Street Health Care Select Sector SPDR ETF (Symbol: XLV) saw new options become available today, for the December 11th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the XLV options chain for the...

SLS Stock’s Big AML Trial Milestone Sparks A Selloff — What’s Fueling Retail’s ‘Extremely Bullish’ Bets?

Retail bulls discussed buying the dip and a potential buyout, while others also challenged survival estimates.

VKTX Stock Slides Overnight After Q3 Loss: CEO’s Obesity Drug Launch Timeline Frustrates Retail

CEO Brian Lian said a potential launch of obesity drug VK2735 remained about 2 and a half years away.

Why Did IOVA Stock Jump Over 10% After-Hours Today? 

Iovance will share positive Phase 2 results for Lifileucel on Thursday, along with a precision-medicine update.

BSX Stock Crashes To 4-Year Lows: Boston Scientific Sees Q4 Sales Declining, CEO Remains Confident In ‘Long-Term Strategy’

For full year 2026, Boston Scientific expects reported sales growth of about 4.25%, down from its previous forecast of 5.5% to 6.5%


Should You Invest in the State Street Health Care Select Sector SPDR ETF ETF (XLV)?

Which Healthcare ETF Is the Better Buy: Fidelity's FHLC or State Street's XLV?

Key PointsState Street Health Care Select Sector SPDR ETF focuses exclusively on S&P 500 healthcare components, leading to a highly concentrated portfolio...

Stocktwits Pharma Pulse: Big Pharma Earnings, Cancer Updates And 2 FDA Deadlines — The Week’s Biotech Watchlist 

Lilly and Merck report earnings on Thursday, followed by AbbVie on Friday.

MRNA Stock’s Vaccine Rally Cracks As Worst Week In 3 Months Looms — Analyst Calls It A ‘Do-Not-Trade’ Over Wild Swings 

Mizuho analyst Jared Holz said the vaccine data weren’t bad, but Wall Street’s expectations were too high.

Select Sector SPDR Trust (The) - State Street Health Care Select Sector SPDR ETF

Bullish Sentiment

<ul class="summary-bullets"><li>China Universal and Mirae added to IOVA and IBRX, while other institutions cut positions.</li><li>IOVA plunged after updated Lifileucel lung-cancer data, despite stronger responses in a selected subgroup.</li><li>Sellas’ Regal trial reached its 80th event, triggering final analysis, with results expected this quarter.</li></ul><p>Sellas Life Sciences (SLS), Iovance Biotherapeutics (IOVA) and ImmunityBio (IBRX) are closing out a difficult October, even as recent filings reveal that Virginia Retirement&nbsp;System entered the month with larger stakes in all three companies.</p><p>So far this month,&nbsp;<a href="https://stocktwits.com/symbol/SLS">SLS</a> has fallen 18%,&nbsp;<a href="https://stocktwits.com/symbol/IOVA">IOVA</a> is down 35% and&nbsp;<a href="https://stocktwits.com/symbol/IBRX">IBRX</a> has lost 7%. All three lagged the&nbsp;<a href="https://stocktwits.com/symbol/XBI">SPDR S&amp;P Biotech ETF (XBI)</a>, which recovered from earlier weakness to trade nearly flat for the month.&nbsp;</p><h2 class="st-heading-2"><strong>Who Added And Who Cut Their Holdings In SLS, IBRX, And IOVA</strong></h2><div><figure class="table"><table class="ck-table-resized"><colgroup><col><col><col><col></colgroup><tbody><tr><td>Stock</td><td>Shares held as of Sept.30</td><td>Shares added</td><td>Increase</td></tr><tr><td>SLS</td><td>26,500</td><td>9,100</td><td>52%</td></tr><tr><td>IOVA</td><td>131,450</td><td>23,400</td><td>22%</td></tr><tr><td>IBRX</td><td>76,000</td><td>1,500</td><td>2%</td></tr></tbody></table></figure></div><p>The pension investor’s three positions were worth nearly $3 million combined at quarter-end.</p><p>Meanwhile, other institutions took different routes: China Universal and Mirae Asset each raised their IOVA and IBRX holdings by 16%, according to Fiscal.ai. Raiffeisen cut its IOVA stake by 26% to 280,000 shares, while Leonteq reduced its holding by 60% to 60,000 shares.</p><p>In SLS, Daiwa nearly exited, cutting its position by 99.9% to 100 shares. Wyoming reduced its stake by 92% to 1,635 shares, while SJS Investment Consulting held steady at 40,000 shares. Parkside’s eye-catching 32,650% increase came from a tiny base: its holding rose from two shares to 655.</p><h2 class="st-heading-2"><strong>Lung-Cancer Data Tests IOVA Bulls</strong></h2><p>Iovance plunged 36% to $9.56 on Thursday after updated Lifileucel lung-cancer data showed a 24.6% response rate in 69 patients, versus 25.6% previously reported in 39. Two responses await confirmation.</p><p>A retrospectively selected subgroup of 22 patients achieved a 59.1% response rate. “In the enriched subgroup, nearly six in ten patients responded, including two complete responses,” interim CEO Frederick Vogt said. Iovance plans to begin enrolling a prospective biomarker-selected cohort in November and targets a 2027 FDA submission for the broader lung-cancer program.</p><p>Lifileucel is already sold as Amtagvi for advanced melanoma. Demand for Amtagvi and Proleukin drove September’s increase in 2026 revenue guidance to $410 million to $420 million from a range of $350 million to $370 million.&nbsp;</p><h2 class="st-heading-2"><strong>A Key Trial Milestone Fails To Lift SLS</strong></h2><p>Sellas fell nearly 15% Wednesday and another 2.2% Thursday to $10.16 after its Phase 3 Regal leukemia trial reached the long-awaited 80th event, meaning 80 deaths.</p><p>The milestone triggers database lock, unblinding and final analysis, with preliminary topline results expected this quarter. “Reaching the 80th event represents a critical milestone in the Regal trial,” CEO Angelos Stergiou said.</p><p>Regal tests Galinpepimut-S (GPS) as maintenance treatment for patients in second complete remission. Results have not yet established whether GPS improved overall survival, the primary endpoint.&nbsp;</p><h2 class="st-heading-2"><strong>IBRX Slides Despite Approval And Trial Progress</strong></h2><p>ImmunityBio’s monthly decline comes despite the FDA’s recent expansion of Anktiva plus BCG’s approval to include BCG-unresponsive bladder cancer with papillary-only tumors, broadening its earlier indication involving carcinoma in situ.</p><p>The next catalyst is November’s readout from Quilt-2.005, a 366-patient trial comparing Anktiva plus BCG with BCG alone in patients who have not previously received BCG. ImmunityBio completed database lock last week and plans a fourth-quarter FDA submission, potentially moving treatment earlier in the disease course. CNBC’s Jim Cramer called ImmunityBio a “very good spec” earlier this week, citing biotech takeover activity.</p><h2 class="st-heading-2"><strong>How Do Retail Traders Feel About SLS, IBRX, IOVA?</strong></h2><p>On Stocktwits, IBRX led retail optimism with ‘extremely bullish’ sentiment and ‘extremely high’ message volume. SLS sentiment was ‘bullish’ amid ‘high’ message volume, while IOVA drew ‘bearish’ sentiment amid ‘low’ activity.&nbsp;</p><p>So far this year, IBRX has surged 341%, IOVA has gained 250% and SLS has climbed 169%, all outpacing XBI’s 30% advance.&nbsp;</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p><p>Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rklb-stock-rocket-lab-nasa-robot-repairs-neutron-advances-100th-electron-ships/cZUh0nZR9RY">RKLB Stock Tests Bulls’ Patience — Rocket Lab’s NASA Robot Eyes Repairs As Neutron Advances, 100th Electron Ships&nbsp;</a></p>

Representative Image (Photo credit: Getty Images)

iShares Biotechnology ETF

ImmunityBio Inc

Iovance Biotherapeutics Inc

SELLAS Life Sciences Group Inc

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$184.87
Prev Close	$184.04
Open	$186.75
Dividend Yield	N/A
50-Day Moving Average	$172.22
Beta	N/A
Avg. Volume	7.94M
PE Ratio	N/A

52-Week High	$187.99
52-Week Low	$141.97
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

XLV Fundamentals